MARKET

PRAH

PRAH

PRA Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

172.30
+1.99
+1.17%
After Hours: 172.30 0 0.00% 16:25 05/07 EDT
OPEN
170.39
PREV CLOSE
170.31
HIGH
173.13
LOW
169.87
VOLUME
664.74K
TURNOVER
--
52 WEEK HIGH
173.13
52 WEEK LOW
86.86
MARKET CAP
11.16B
P/E (TTM)
52.75
1D
5D
1M
3M
1Y
5Y
The Vanguard Health Care Fund Cuts Abbott Labs, Thermo Fisher
GuruFocus News · 1d ago
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 1d ago
Global Pharmacovigilance Outsourcing Market 2021, Segment by Types, Share, Growth, Application and Forecast to 2027 | Key Vendors are-Bioclinica, Parexel, MarksMan Healthcare, Oracle Corporation
May 06, 2021 (The Expresswire) -- The report on the Pharmacovigilance Outsourcing market provides a market analysis complete with a quantitative and...
The Express Wire · 2d ago
Pharmacovigilance Market is Expected to Witness Rapid Growth by 2031 | PRA Health Sciences Inc., Quintiles Transnational Holdings Inc., Sanofi SA, Synowledge LLC and Wipro Ltd. among Others
Markitwired · 2d ago
Contract Research Organizations (CRO) Market (Based on 2020 COVID-19 Worldwide Spread) 2021 Industry Analysis, Trends, and Forecast 2027
May 06, 2021 (Heraldkeepers) -- Meticulous Research(R)- leading global market research company, published a research report titled "CROs Market by Services...
Heraldkeepers · 2d ago
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 2d ago
Contract Research Organization Market Production, Consumption, Worldwide Business, Revenue, Price Trend by Product Type, Analysis by 2023
May 06, 2021 (Heraldkeepers) -- The Report of Global Contract Research Organization Market by Market Research Future Covers the Information like Global...
Heraldkeepers · 2d ago
Data Monitoring Committees in the Changing Landscape of Clinical Trials, Upcoming Webinar Hosted by Xtalks
TORONTO, May 5, 2021 /PRNewswire via COMTEX/ -- TORONTO, May 5, 2021 /PRNewswire-PRWeb/ -- Implementing data monitoring committees (DMCs) for the rapidly...
PR Newswire - PRF · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRAH. Analyze the recent business situations of PRA Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRAH stock price target is 170.00 with a high estimate of 196.00 and a low estimate of 160.00.
EPS
Institutional Holdings
Institutions: 505
Institutional Holdings: 66.82M
% Owned: 103.12%
Shares Outstanding: 64.80M
TypeInstitutionsShares
Increased
111
2.34M
New
37
484.70K
Decreased
101
1.64M
Sold Out
28
647.86K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/President/Chief Executive Officer/Director
Colin Shannon
Chief Financial Officer/Executive Vice President
Michael Bonello
Executive Vice President/Chief Administrative Officer/General Counsel
Christopher Gaenzle
Lead Director/Independent Director
James Momtazee
Independent Director
Jeffrey Barber
Independent Director
Alexander Dickinson
Independent Director
Linda Grais
Independent Director
Glen Stettin
Independent Director
Matthew Young
No Data
  • All
  • Financials
  • Insiders
More
About PRAH
PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company's service offerings include product registration, strategic solutions and early development services.

Webull offers kinds of PRA Health Sciences Inc stock information, including NASDAQ:PRAH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRAH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRAH stock methods without spending real money on the virtual paper trading platform.